ChongYang Liang

author: Time:2022-02-09 Number of hits:

姓名

ChongYang Liang

职称

Associate Professor

办公地点

Room 214,Regeneration Institute

办公电话

85619387

邮箱

liang@jlu.edu.cn

教育背景

2004-09 to 2009-07 Ph.D.,Biochemistry and molecular biology, Jilin University

2000-09 to 2004-07 Bachelor,Biotechnology major,Northeast Forestry University

工作经历

2009-09- Associate Professor, doctoral supervisor,College of pharmacy, Jilin University

主讲课程

Undergraduate course:fermentation engeneering

Postgraduate course:modern biological experimental technology

研究领域

1.Ultra high throughput targeted drug screening and molecular fishing technology

A new high-throughput drug screening method was developed by using micro nano molecular assembly combined with Raman spectroscopy technology. More than ten targeted screening platforms were established for cancer, diabetes and hyperlipidemia indications. At the same time, the high-throughput drug screening technology was applied to all kinds of compound libraries, such as natural product molecular library, combinatorial chemical molecular library, etc, It can be used for the rapid drug fishing screening of molecular libraries in various fields, which can achieve the technical ability of rapid, sensitive and high-throughput screening.

2. On site rapid detection technology based on gene editing

A novel non amplified nucleic acid on-site rapid detection technology was developed by combining cas12a, cas13a and dcas9 gene editing elements with electrochemical, single molecule catalytic and optical sensing technologies.

3. Spatial transcriptome

The development of spatial transcriptome technology that can achieve single-cell and subcellular resolution, and the fusion of biological patterns and genomic information will help to understand and explain the biological mechanism of development and tumor from the perspective of time and space.

4. New sequencing technology

To study the complex DNA enzyme interaction system in the current sequencing technology, and to develop efficient DNA sequencing enzyme system, isothermal sequencing enzyme system.

科研成果

(1)Dan Sun, Weiqing Xu, Chongyang Liang*, Wei Shi and Shuping Xu*. Smart Surface-Enhanced Resonance Raman Scattering Nanoprobe for Monitoring Cellular Alkaline Phosphatase Activity during Osteogenic Differentiation[J]. ACS Sensors, 2020, 5(6):1758-1767. 一区(IF: 7.333)

(2)Jing Yue, Yanting Shen, Lijia Liang, Xin Guan, Xue Zhang, Shuping Xu*, Chongyang Liang*, Wei Shi and Weiqing Xu. Tracing the molecular dynamics of living mitochondria under phototherapy via surface-enhanced Raman scattering spectroscopy[J]. The Analyst, 2019, 144. 二区 (IF: 3.978)

(3)Jing Yue, Lijia Liang, Yanting Shen, Xin Guan, Jing Zhang, Zhiyuan Li, Rong Deng, Shuping Xu, Chongyang Liang*, Wei Shi and Weiqing Xu*. Investigating Dynamic Molecular Events in Melanoma Cell Nucleus During Photodynamic Therapy by SERS. Front Chem. 2019 Jan 28;6:665. 二区(IF: 3.693)

(4)Rong Deng, Jing Yue, Huixin Qu, Lijia Liang, Dan Sun, Jing Zhang, Chongyang Liang*, Weiqing Xu and Shuping Xu*. Glucose-bridged silver nanoparticle assemblies for highly sensitive molecular recognition of sialic acid on cancer cells via surface-enhanced raman scattering spectroscopy[J]. Talanta, 2018, 179:200-206. 二区 (IF: 5.339)

(5)Yanting Shen, Shuping Xu*, Chongyang Liang*, et al. Organelle-targeting surface-enhanced Raman scattering (SERS) nanosensors for subcellular pH sensing[J]. Nanoscale, 2018, 10(4): 1622-1630. 一区 (IF: 6.895)

(6)Yanting Shen, Shuping Xu*, Chongyang Liang*, et al. Organelle-Targeting Gold Nanorods for Macromolecular Profiling of Subcellular Organelles and Enhanced Cancer Cell Killing[J]. ACS Applied Materials & Interfaces, 2018, 10(9): 7910-7918. 一区 (IF: 8.758)

(7)Jing Zhang, Shuping Xu*, Chongyang Liang*, et al. In situ, accurate, surface-enhanced Raman scattering detection of cancer cell nucleus with synchronous location by an alkyne-labeled biomolecular probe[J]. Analytical & Bioanalytical Chemistry, 2018, 410(2): 585-594. 三区 (IF: 3.637)

(8)Jing Jin, Fei Sun, Shuping Xu*, Chongyang Liang*, et al. In situ exploration of characteristics of macropinocytosis and size range of internalized substances in cells by 3D-structured illumination microscopy[J]. International journal of nanomedicine, 2018, 13: 5321. 二区 (IF: 5.115)

(9)Lijia Liang, Shuping Xu*, Chongyang Liang*, et al. Tracing sialoglycans on cell membrane via surface-enhanced Raman scattering spectroscopy with a phenylboronic acid-based nanosensor in molecular recognition[J]. Biosensors & Bioelectronics, 2017, 94: 148. 一区 (IF:10.257)

(11)Rong Deng, Shuping Xu*, Chongyang Liang*, et al. Tracing the Therapeutic Process of Targeted Aptamer/Drug Conjugate on Cancer Cells by Surface-Enhanced Raman Scattering Spectroscopy[J]. Analytical Chemistry, 2017, 89(5): 2844. 一区 (IF: 6.785)

(12)Lu Dai,Weikang Li,Fei Sun,Baizhi Li,Hongrui Li,Hongxing Zhang*,Qingchuan Zheng*,Chongyang Liang*. A strategy of designing the ligand of antibody affinity chromatography based on molecular dynamics simulation[J]. Journal of Chromatography A,2016,1463:81-89. 二区 (IF: 4.049)

(13)Lijia Liang, Chongyang Liang*, Weiqing Xu*, et al. In Situ Surface-Enhanced Raman Scattering Spectroscopy Exploring Molecular Changes of Drug-Treated Cancer Cell Nucleus[J]. Analytical Chemistry, 2015, 87(4): 2504. 一区. (IF: 6.785)

专利:

1、专利名称:基于拉曼光谱和微液滴技术的单克隆抗体制备方法,申报人(排序):梁重阳,徐抒平,申请年份:2018-12-31,申请号:2018116503884,批准年份:2020-10-30,专利号:2018116503884,

2、专利名称:一种抗体亲和配体的设计方法,申报人(排序):孙非;梁重阳;戴璐,申请年份:2016-08-05,申请号:2016106322794,批准年份:2020-10-30,专利号:2016106322794, 3、专利名称:重组灵芝免疫调节蛋白(rlz-8)在制备治疗组织纤维化药物中的应用,申报人(排序):张喜田;孙非;梁重阳,申请年份:2014-10-04,申请号:2014100487135,批准年份:2017-10-04,专利号:2014100487135

4、专利名称:重组灵芝免疫调节蛋白在制备治疗局灶性脑缺血药物中的应用,申报人(排序):孙非;梁重阳;张喜田,申请年份:2013-10-04,申请号:2013104022594,批准年份:2017-06-30,专利号:2013104022594。

5、专利名称:重组灵芝免疫调节蛋白(rlz-8)在制备治疗黑色素瘤药物中的应用,申报人(排序):梁重阳,申请年份:2013-10-03,申请号:2013103571768,批准年份:2017-10-25,专利号:2013103571768。

6、专利名称:重组灵芝免疫调节蛋白单甲氧基聚乙二醇丙酸琥珀酰亚胺酯修饰物、制备方法和用途,申报人(排序):孙非;梁重阳;张喜田,申请年份:2012-10-02,专利号:2012102435827。

转化情况: 本团队主导设计和实施的新药开发项目,灵芝免疫调节蛋白突变体相应的冻干粉针剂已被美国FDA(2020年1月)和中国NMPA(2020年5月)批准进行临床试验,研发期间发表相关学术文章十余篇,获得授权的国内外专利超过20项。该项目是我国首个新分子构型的蛋白质药物获批FDA临床研究,整个项目吸引社会资本5亿元,于2017年完成建厂,建筑面积50000平米,研发期间已解决百余人的就业。

本团队利用微流控打印技术发展新型空间转录组芯片制造技术,新型Barcode设计已获国内该领域龙头企业“烈冰生物”转化,将共同联合开发分辨率达到亚细胞级别的空转打印方法,同时建立相关的图形识别和生信计算算法和数据库。

Copyright: School of Pharmacy